Eupraxia Pharmaceuticals has closed a public offering that raised $63.2 million, including the full exercise of underwriter options to purchase additional shares. The capital raise strengthens the biopharmaceutical company's financial position as it advances its clinical development programs.
The company intends to deploy the offering proceeds primarily toward advancing EP-104GI through Phase 2 and Phase 3 clinical trials for eosinophilic esophagitis, a chronic inflammatory condition of the esophagus. Additional funds will support the expansion of pipeline candidates across other gastrointestinal indications and bolster commercial readiness infrastructure in preparation for potential product launches.
The completed offering demonstrates investor confidence in Eupraxia's gastrointestinal disease platform at a time when the company accelerates its clinical programs. The capital injection provides runway for the company to progress its lead candidate through key development milestones over the coming years.